TY - JOUR AU - Flores-Mireles, A. L. AU - Walker, J. N. AU - Caparon, M. AU - Hultgren, S. J. PY - 2015 DA - 2015// TI - Urinary tract infections: epidemiology, mechanisms of infection and treatment options JO - Nat Rev Microbiol VL - 13 UR - https://doi.org/10.1038/nrmicro3432 DO - 10.1038/nrmicro3432 ID - Flores-Mireles2015 ER - TY - BOOK PY - 2013 DA - 2013// TI - SWAB Guidelines for Antimicrobial Therapy of Complicated Urinary Tract Infections in Adults ID - ref2 ER - TY - JOUR AU - Gupta, K. AU - Hooton, T. M. AU - Naber, K. G. AU - Wullt, B. AU - Colgan, R. AU - Miller, L. G. PY - 2011 DA - 2011// TI - International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases JO - Clin Infect Dis VL - 52 UR - https://doi.org/10.1093/cid/ciq257 DO - 10.1093/cid/ciq257 ID - Gupta2011 ER - TY - JOUR AU - Wagenlehner, F. M. AU - Sobel, J. D. AU - Newell, P. AU - Armstrong, J. AU - Huang, X. AU - Stone, G. PY - 2016 DA - 2016// TI - Ceftazidime-avibactam versus Doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program JO - Clin Infect Dis VL - 61 ID - Wagenlehner2016 ER - TY - JOUR AU - Naber, K. G. AU - Llorens, L. AU - Kaniga, K. AU - Kotey, P. AU - Hedrich, D. AU - Redman, R. PY - 2009 DA - 2009// TI - Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis JO - Antimicrob Agents Chemother VL - 53 UR - https://doi.org/10.1128/AAC.00837-08 DO - 10.1128/AAC.00837-08 ID - Naber2009 ER - TY - STD TI - National institute of Public health and the Environment. Nethmap/Maran 2018 [Internet]. 2018. Available from: http://www.swab.nl/swab/cms3.nsf/viewdoc/20BCD3983B5C390AC12575850031D33D. UR - http://www.swab.nl/swab/cms3.nsf/viewdoc/20BCD3983B5C390AC12575850031D33D ID - ref6 ER - TY - JOUR AU - Starre, W. E. AU - Nieuwkoop, C. AU - Paltansing, S. AU - van’t Wout, J. W. AU - Groeneveld, G. H. AU - Becker, M. J. PY - 2011 DA - 2011// TI - Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection JO - J Antimicrob Chemother VL - 66 UR - https://doi.org/10.1093/jac/dkq465 DO - 10.1093/jac/dkq465 ID - Starre2011 ER - TY - JOUR AU - Veve, M. P. AU - Wagner, J. L. AU - Kenney, R. M. AU - Grunwald, J. L. AU - Davis, S. L. PY - 2016 DA - 2016// TI - Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum Beta-lactamase urinary tract infections JO - Int J Antimicrob Agents VL - 48 UR - https://doi.org/10.1016/j.ijantimicag.2016.04.014 DO - 10.1016/j.ijantimicag.2016.04.014 ID - Veve2016 ER - TY - JOUR AU - Senol, S. AU - Tasbakan, M. AU - Pullukcu, H. AU - Sipahi, O. R. AU - Sipahi, H. AU - Yamazhan, T. PY - 2010 DA - 2010// TI - Carbapenem versus Fosfomycin Tromethanol in the treatment of extended-Spectrum Beta-lactamase-producing Escherichia Coli -related complicated lower urinary tract infection JO - J Chemother VL - 22 UR - https://doi.org/10.1179/joc.2010.22.5.355 DO - 10.1179/joc.2010.22.5.355 ID - Senol2010 ER - TY - STD TI - Surber C. Product monograph of monurol. 2016;(version 4.0). Available from: http://www.paladin-labs.com/our_products/Monurol-Sachet-PM-En.pdf UR - http://www.paladin-labs.com/our_products/Monurol-Sachet-PM-En.pdf ID - ref10 ER - TY - JOUR AU - Dettori, J. PY - 2010 DA - 2010// TI - The random allocation process: two things you need to know JO - Evid Based Spine Care J VL - 1 UR - https://doi.org/10.1055/s-0030-1267062 DO - 10.1055/s-0030-1267062 ID - Dettori2010 ER - TY - JOUR AU - Nieuwkoop, C. AU - Starre, W. E. AU - Stalenhoef, J. E. AU - Aartrijk, A. M. AU - Reijden, T. J. K. AU - Vollaard, A. M. PY - 2017 DA - 2017// TI - Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women JO - BMC Med VL - 15 UR - https://doi.org/10.1186/s12916-017-0835-3 DO - 10.1186/s12916-017-0835-3 ID - Nieuwkoop2017 ER - TY - JOUR AU - Sandberg, T. AU - Skoog, G. AU - Hermansson, A. B. AU - Kahlmeter, G. AU - Kuylenstierna, N. AU - Lannergård, A. PY - 2012 DA - 2012// TI - Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial JO - Lancet VL - 380 UR - https://doi.org/10.1016/S0140-6736(12)60608-4 DO - 10.1016/S0140-6736(12)60608-4 ID - Sandberg2012 ER - TY - JOUR AU - Grayson, M. L. AU - Macesic, N. AU - Trevillyan, J. AU - Ellis, A. G. AU - Zeglinski, P. T. AU - Hewitt, N. H. PY - 2015 DA - 2015// TI - Fosfomycin for treatment of prostatitis: new tricks for old dogs JO - Clin Infect Dis VL - 61 UR - https://doi.org/10.1093/cid/civ436 DO - 10.1093/cid/civ436 ID - Grayson2015 ER - TY - JOUR AU - Falagas, M. E. AU - Kastoris, A. C. AU - Kapaskelis, A. M. AU - Karageorgopoulos, D. E. PY - 2010 DA - 2010// TI - Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum Beta-lactamase producing, Enterobacteriaceae infections: a systematic review JO - Lancet Infect Dis VL - 10 UR - https://doi.org/10.1016/S1473-3099(09)70325-1 DO - 10.1016/S1473-3099(09)70325-1 ID - Falagas2010 ER - TY - JOUR AU - Wagenlehner, F. M. AU - Umeh, O. AU - Steenbergen, J. AU - Yuan, G. AU - Darouiche, R. O. PY - 2015 DA - 2015// TI - Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI) JO - Lancet VL - 385 UR - https://doi.org/10.1016/S0140-6736(14)62220-0 DO - 10.1016/S0140-6736(14)62220-0 ID - Wagenlehner2015 ER - TY - JOUR AU - Bratton, D. J. AU - Williams, H. C. AU - Kahan, B. C. AU - Phillips, P. P. AU - Nunn, a. J. PY - 2012 DA - 2012// TI - When inferiority meets non-inferiority: implications for interim analyses JO - Clin Trials VL - 9 UR - https://doi.org/10.1177/1740774512453220 DO - 10.1177/1740774512453220 ID - Bratton2012 ER - TY - JOUR AU - Rosso-Fernández, C. AU - Sojo-Dorado, J. AU - Barriga, A. AU - Lavín-Alconero, L. AU - Palacios, Z. AU - López-Hernández, I. PY - 2015 DA - 2015// TI - Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial JO - BMJ Open VL - 5 UR - https://doi.org/10.1136/bmjopen-2014-007363 DO - 10.1136/bmjopen-2014-007363 ID - Rosso-Fernández2015 ER - TY - JOUR AU - Sevinc, F. AU - Prins, J. M. AU - Koopmans, R. AU - Langendijk, P. N. J. AU - Bossuyt, P. M. M. AU - Dankert, J. AU - Speelman, P. PY - 1999 DA - 1999// TI - Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital JO - J Antimicrob Chemother VL - 43 UR - https://doi.org/10.1093/jac/43.4.601 DO - 10.1093/jac/43.4.601 ID - Sevinc1999 ER - TY - JOUR AU - Hendlin, D. AU - Stapley, E. O. AU - Jackson, M. AU - Wallick, H. AU - Miller, A. K. AU - Wolf, F. J. PY - 1969 DA - 1969// TI - Phosphonomycin, a new antibiotic produced by strains of streptomyces JO - Science VL - 166 UR - https://doi.org/10.1126/science.166.3901.122 DO - 10.1126/science.166.3901.122 ID - Hendlin1969 ER - TY - JOUR AU - Bergan, T. o. m. AU - Thorsteinsson, S. i. g. u. r. d. u. r. B. AU - Albini, E. n. r. i. c. o. PY - 1993 DA - 1993// TI - Pharmacokinetic Profile of Fosfomycin Trometamol JO - Chemotherapy VL - 39 UR - https://doi.org/10.1159/000239140 DO - 10.1159/000239140 ID - Bergan1993 ER - TY - JOUR AU - Vardakas, K. Z. AU - Legakis, N. J. AU - Triarides, N. AU - Falagas, M. E. PY - 2016 DA - 2016// TI - Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature JO - Int J Antimicrob Agents VL - 47 UR - https://doi.org/10.1016/j.ijantimicag.2016.02.001 DO - 10.1016/j.ijantimicag.2016.02.001 ID - Vardakas2016 ER - TY - JOUR AU - Wijma, R. A. AU - Koch, B. C. P. AU - Gelder, T. AU - Mouton, J. W. PY - 2018 DA - 2018// TI - High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers JO - Clin Microbiol Infect VL - 24 UR - https://doi.org/10.1016/j.cmi.2017.08.023 DO - 10.1016/j.cmi.2017.08.023 ID - Wijma2018 ER - TY - BOOK AU - Wenzler, E. AU - Ellis-Grosse, E. J. AU - Rodvold, K. A. PY - 2017 DA - 2017// TI - Pharmacokinetics, Safety, and Tolerability of Single Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers. Antimicrob Agents Chemother [Internet] ID - Wenzler2017 ER - TY - BOOK PY - 2017 DA - 2017// TI - NethMap/Maran 2017; Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands [internet] ID - ref25 ER - TY - JOUR AU - Cho, Y. H. AU - Il, J. S. AU - Chung, H. S. AU - Yu, H. S. AU - Hwang, E. C. AU - Kim, S. O. PY - 2015 DA - 2015// TI - Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin JO - Int Urol Nephrol VL - 47 UR - https://doi.org/10.1007/s11255-015-1018-9 DO - 10.1007/s11255-015-1018-9 ID - Cho2015 ER - TY - STD TI - van den Bijllaardt W, Schijffelen MJ, Bosboom RW, Cohen Stuart J, Diederen B, Kampinga G, et al. Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion. J Antimicrob Chemother [Internet]. 2018;(July):2380–2387. Available from: https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dky214/5047839 UR - https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dky214/5047839 ID - ref27 ER -